The global pneumonia vaccines market size was worth $7.15 billion in 2018, and is expected to reach $10.35 billion by 2026, growing at a CAGR of 5.2% from 2019 to 2026. The research offers a detailed analysis on changing market dynamics, key investment pockets, major segments, and market competition.
Growing incidence of pneumonia globally, increased government focus on immunization programs for pneumonia, and rise in focus for new pneumococcal vaccines propel the market growth. However, longer timelines required for pneumonia vaccine production and high cost associated with the development of such vaccines restrain the growth of the market. Conversely, the development of protein-based combination pneumococcal vaccines creates new opportunities for the growth of the market.
The report analyzes and forecasts the pneumonia vaccines market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global pneumonia vaccines market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the pneumonia vaccines market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of pneumonia vaccines market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Key Players:
The report provides an extensive competitive analysis and profiles of the key market players such as Glaxosmithkline plc., LG Chem Ltd., Merck & Co., Inc., Panacea Biotec Limited, Pfizer Inc., Pnuvax Incorporated, Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd. (Beijing Minhai Biotechnology Corporation Limited), SK Bioscience and Walvax Biotechnology Co., Ltd.
Segmentation:
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
Section 1: INTRODUCTION
1.1. Market Report description
1.2. Market Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
Section 2: EXECUTIVE SUMMARY
2.1. Market Key findings of the study
2.2. CXO perspective
Section 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies, 2016–2018
3.2.3. Top strategies:
3.3. Porters five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Threat of new entrants
3.3.3. Threat of substitutes
3.3.4. Competitive rivalry
3.3.5. Bargaining power among buyers
3.4. Market share analysis, 2018
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Surge in prevalence of pneumonia across the globe
3.5.1.2. Rise in government focus on immunization programs for pneumonia
3.5.1.3. Increase in focus for novel pneumococcal vaccines
3.5.2. Restraints
3.5.2.1. Longer timelines required for pneumonia vaccine production
3.5.2.2. High cost associated with development of such vaccines
3.5.3. Opportunity
3.5.3.1. Development of protein-based combination pneumococcal vaccines
Section 4: PNEUMONIA VACCINES MARKET, BY VACCINE TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Pneumococcal conjugate vaccine (PCV)
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast
4.3. Pneumococcal polysaccharide vaccine (PPSV/PPV)
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast
Section 5: PNEUMONIA VACCINES MARKET, BY PRODUCT TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Prevnar 13
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast
5.3. Synflorix
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast
5.4. Pneumovax23
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast
5.5. Pipeline Products
Section 6: PNEUMONIA VACCINES MARKET, BY SECTOR
6.1. Overview
6.1.1. Market size and forecast
6.2. Public sector
6.2.1. Market size and forecast
6.3. Private sector
6.3.1. Market size and forecast
Section 7: PNEUMONIA VACCINES MARKET, BY DISTRIBUTION CHANNEL
7.1. Overview
7.1.1. Market size and forecast
7.2. Distribution partner companies
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast
7.3. Non-governmental Organizations (NGO)
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast
7.4. Government Authorities
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast
Section 8: GLOBAL PNEUMONIA MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast
8.2. North America
8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast, by type
8.2.4. Market size and forecast, by product type
8.2.5. Market size and forecast, by distribution channel
8.2.6. Market size and forecast, by sector
8.2.7. Market size and forecast, by country
8.2.7.1. The U.S. Pneumonia Vaccine Market
8.2.7.1.1. Market Size and forecast, by type
8.2.7.1.2. Market Size and forecast, by product type
8.2.7.1.3. Market Size and forecast, by distribution channel
8.2.7.1.4. Market Size and forecast, by sector
8.2.7.2. Canada Pneumonia Vaccine Market
8.2.7.2.1. Market Size and forecast, by type
8.2.7.2.2. Market Size and forecast, by product type
8.2.7.2.3. Market Size and forecast, by distribution channel
8.2.7.2.4. Market Size and forecast, by sector
8.2.7.3. Mexico Pneumonia Vaccine Market
8.2.7.3.1. Market Size and forecast, by type
8.2.7.3.2. Market Size and forecast, by product type
8.2.7.3.3. Market Size and forecast, by distribution channel
8.2.7.3.4. Market Size and forecast, by sector
8.3. Europe
8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast, by type
8.3.4. Market size and forecast, by product type
8.3.5. Market size and forecast, by distribution channel
8.3.6. Market size and forecast, by sector
8.3.7. Market size and forecast, by country
8.3.7.1. Germany Pneumonia Vaccine Market
8.3.7.1.1. Market Size and forecast, by type
8.3.7.1.2. Market Size and forecast, by product type
8.3.7.1.3. Market Size and forecast, by distribution channel
8.3.7.1.4. Market Size and forecast, by sector
8.3.7.2. France Pneumonia Vaccine Market
8.3.7.2.1. Market Size and forecast, by type
8.3.7.2.2. Market Size and forecast, by product type
8.3.7.2.3. Market Size and forecast, by distribution channel
8.3.7.2.4. Market Size and forecast, by sector
8.3.7.3. UK Pneumonia Vaccine Market
8.3.7.3.1. Market Size and forecast, by type
8.3.7.3.2. Market Size and forecast, by product type
8.3.7.3.3. Market Size and forecast, by distribution channel
8.3.7.3.4. Market Size and forecast, by sector
8.3.7.4. Spain Pneumonia Vaccine Market
8.3.7.4.1. Market Size and forecast, by type
8.3.7.4.2. Market Size and forecast, by product type
8.3.7.4.3. Market Size and forecast, by distribution channel
8.3.7.4.4. Market Size and forecast, by sector
8.3.7.5. Italy Pneumonia Vaccine Market
8.3.7.5.1. Market Size and forecast, by type
8.3.7.5.2. Market Size and forecast, by product type
8.3.7.5.3. Market Size and forecast, by distribution channel
8.3.7.5.4. Market Size and forecast, by sector
8.3.7.6. Rest of Europe Pneumonia Vaccine Market
8.3.7.6.1. Market Size and forecast, by type
8.3.7.6.2. Market Size and forecast, by product type
8.3.7.6.3. Market Size and forecast, by distribution channel
8.3.7.6.4. Market Size and forecast, by sector
8.4. Asia-Pacific
8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast, by type
8.4.4. Market size and forecast, by product type
8.4.5. Market size and forecast, by distribution channel
8.4.6. Market size and forecast, by sector
8.4.7. Market size and forecast, by country
8.4.7.1. Japan Pneumonia Vaccine Market
8.4.7.1.1. Market Size and forecast, by type
8.4.7.1.2. Market Size and forecast, by product type
8.4.7.1.3. Market Size and forecast, by distribution channel
8.4.7.1.4. Market Size and forecast, by sector
8.4.7.2. China Pneumonia Vaccine Market
8.4.7.2.1. Market Size and forecast, by type
8.4.7.2.2. Market Size and forecast, by product type
8.4.7.2.3. Market Size and forecast, by distribution channel
8.4.7.2.4. Market Size and forecast, by sector
8.4.7.3. India Pneumonia Vaccine Market
8.4.7.3.1. Market Size and forecast, by type
8.4.7.3.2. Market Size and forecast, by product type
8.4.7.3.3. Market Size and forecast, by distribution channel
8.4.7.3.4. Market Size and forecast, by sector
8.4.7.4. Rest of Asia-Pacific Pneumonia Vaccine Market
8.4.7.4.1. Market Size and forecast, by type
8.4.7.4.2. Market Size and forecast, by product type
8.4.7.4.3. Market Size and forecast, by distribution channel
8.4.7.4.4. Market Size and forecast, by sector
8.5. LAMEA
8.5.1. Key market trends
8.5.2. Key growth factors and opportunities
8.5.3. Market size and forecast, by type
8.5.4. Market size and forecast, by product type
8.5.5. Market size and forecast, by distribution channel
8.5.6. Market size and forecast, by sector
8.5.7. Market size and forecast, by country
8.5.7.1. Brazil Pneumonia Vaccine Market
8.5.7.1.1. Market Size and forecast, by type
8.5.7.1.2. Market Size and forecast, by product type
8.5.7.1.3. Market Size and forecast, by distribution channel
8.5.7.1.4. Market Size and forecast, by sector
8.5.7.2. South Africa Pneumonia Vaccine Market
8.5.7.2.1. Market Size and forecast, by type
8.5.7.2.2. Market Size and forecast, by product type
8.5.7.2.3. Market Size and forecast, by distribution channel
8.5.7.2.4. Market Size and forecast, by sector
8.5.7.3. Saudi Arabia Pneumonia Vaccine Market
8.5.7.3.1. Market Size and forecast, by type
8.5.7.3.2. Market Size and forecast, by product type
8.5.7.3.3. Market Size and forecast, by distribution channel
8.5.7.3.4. Market Size and forecast, by sector
8.5.7.4. Rest of LAMEA Pneumonia Vaccine Market
8.5.7.4.1. Market Size and forecast, by type
8.5.7.4.2. Market Size and forecast, by product type
8.5.7.4.3. Market Size and forecast, by distribution channel
8.5.7.4.4. Market Size and forecast, by sector
Section 9: COMPANY PROFILES
9.1. GLAXOSMITHKLINE PLC.
9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product Portfolio
9.1.5. Business performance
9.2. LG CHEM LTD.
9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product portfolio
9.2.5. Business performance
9.3. MERCK & CO., INC.
9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product Portfolio
9.3.5. Business performance
9.4. PANACEA BIOTEC LIMITED
9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product portfolio
9.4.5. Business performance
9.5. PFIZER INC.
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance
9.6. PNUVAX INCORPORATED
9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Product portfolio
9.7. SERUM INSTITUTE OF INDIA PVT. LTD.
9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Product portfolio
9.8. SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD. (BEIJING MINHAI BIOTECHNOLOGY CORPORATION LIMITED)
9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Product portfolio
9.9. SK BIOSCIENCE
9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Product portfolio
9.10. WALVAX BIOTECHNOLOGY CO., LTD.
9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Product Portfolio
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers